Mycenax Biotech Inc. (TPEX:4726)

Mycenax Biotech Statistics

Total Valuation

Mycenax Biotech has a market cap or net worth of TWD 6.42 billion. The enterprise value is 7.27 billion.

Market Cap	6.42B
Enterprise Value	7.27B

Important Dates

The last earnings date was Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Mycenax Biotech has 207.20 million shares outstanding. The number of shares has increased by 0.36% in one year.

Current Share Class	207.20M
Shares Outstanding	207.20M
Shares Change (YoY)	+0.36%
Shares Change (QoQ)	-0.71%
Owned by Insiders (%)	1.37%
Owned by Institutions (%)	0.20%
Float	115.82M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.68
PB Ratio	4.02
P/TBV Ratio	4.12
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-16.21
EV / Sales	9.82
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-62.80

Financial Position

The company has a current ratio of 0.70, with a Debt / Equity ratio of 0.67.

Current Ratio	0.70
Quick Ratio	0.33
Debt / Equity	0.67
Debt / EBITDA	n/a
Debt / FCF	-9.27
Interest Coverage	-11.99

Financial Efficiency

Return on equity (ROE) is -24.77% and return on invested capital (ROIC) is -9.05%.

Return on Equity (ROE)	-24.77%
Return on Assets (ROA)	-7.61%
Return on Invested Capital (ROIC)	-9.05%
Return on Capital Employed (ROCE)	-18.74%
Weighted Average Cost of Capital (WACC)	6.83%
Revenue Per Employee	1.91M
Profits Per Employee	-1.16M
Employee Count	387
Asset Turnover	0.22
Inventory Turnover	9.32

Taxes

Income Tax	-5.48M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -24.57% in the last 52 weeks. The beta is 0.60, so Mycenax Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.60
52-Week Price Change	-24.57%
50-Day Moving Average	33.26
200-Day Moving Average	35.41
Relative Strength Index (RSI)	37.26
Average Volume (20 Days)	303,744

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mycenax Biotech had revenue of TWD 740.24 million and -448.63 million in losses. Loss per share was -2.17.

Revenue	740.24M
Gross Profit	-181.41M
Operating Income	-403.84M
Pretax Income	-454.11M
Net Income	-448.63M
EBITDA	-119.51M
EBIT	-403.84M
Loss Per Share	-2.17

Balance Sheet

The company has 225.75 million in cash and 1.07 billion in debt, with a net cash position of -847.89 million or -4.09 per share.

Cash & Cash Equivalents	225.75M
Total Debt	1.07B
Net Cash	-847.89M
Net Cash Per Share	-4.09
Equity (Book Value)	1.60B
Book Value Per Share	7.78
Working Capital	-330.04M

Cash Flow

In the last 12 months, operating cash flow was -27.24 million and capital expenditures -88.54 million, giving a free cash flow of -115.78 million.

Operating Cash Flow	-27.24M
Capital Expenditures	-88.54M
Depreciation & Amortization	284.33M
Net Borrowing	89.48M
Free Cash Flow	-115.78M
FCF Per Share	-0.56

Margins

Gross margin is -24.51%, with operating and profit margins of -54.56% and -60.61%.

Gross Margin	-24.51%
Operating Margin	-54.56%
Pretax Margin	-61.35%
Profit Margin	-60.61%
EBITDA Margin	-16.15%
EBIT Margin	-54.56%
FCF Margin	n/a

Dividends & Yields

Mycenax Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.36%
Shareholder Yield	-0.36%
Earnings Yield	-6.98%
FCF Yield	-1.80%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Mycenax Biotech has an Altman Z-Score of 2.23 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.23
Piotroski F-Score	4